Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection

[1]  B. Lipworth,et al.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[2]  P. Ravaud,et al.  Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data , 2020, BMJ.

[3]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[4]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[5]  Matthias Klein,et al.  Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients , 2020, medRxiv.

[6]  D. Sin,et al.  ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 , 2020, European Respiratory Journal.

[7]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[8]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[9]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[10]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[11]  M. Shimojima,et al.  The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 , 2020, bioRxiv.

[12]  Zhaofeng Chen,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[13]  Michael Roth,et al.  Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.

[14]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[16]  B. Lipworth,et al.  Journal Pre-proof Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020 .

[17]  Thomas B. Clarke,et al.  Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease , 2019, Science Translational Medicine.

[18]  B. Lipworth,et al.  Current appraisal of single inhaler triple therapy in COPD , 2018, International journal of chronic obstructive pulmonary disease.

[19]  S. Johnston,et al.  Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations , 2018, Nature Communications.

[20]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[21]  S. Suissa,et al.  Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi‐cohort study , 2017, British journal of clinical pharmacology.

[22]  S. Suissa,et al.  Precision Medicine Urgency: The Case of Inhaled Corticosteroids in COPD , 2017, Chest.

[23]  Yoshimasa Tanaka,et al.  TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections , 2017, Biochimie.

[24]  P. Hertzog,et al.  Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon , 2014, Scientific Reports.

[25]  I. Pavord,et al.  Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis , 2014, European Respiratory Journal.

[26]  W. Lim,et al.  Differences between asthmatics and nonasthmatics hospitalised with influenza A infection , 2012, European Respiratory Journal.

[27]  D. Sin,et al.  Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. , 2011, American journal of respiratory cell and molecular biology.

[28]  L. Mayer,et al.  Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. , 1993, The Journal of rheumatology.